MyFinsight
Home
Blog
About
Contact
Download
Download image
Long Acting
Beta2Agonist Relvar Breo
$204,021K
Long Acting
Beta2Agonist Anoro
$46,281K
Total royalties
$250,302K
Xacduro
$74,393K
Giapreza
$73,611K
Xerava
$23,516K
ZEVTERA
$610K
Royalty
$236,479K
Product
$172,130K
License And Other
Revenue
$2,719K
Less amortization of
capitalized fees paid
$13,823K
Total revenue
$411,328K
Gross profit
$307,667K
Cost of products sold
(inclusive of amortization...
$77,384K
Amortization of acquired
intangible assets
$26,277K
Income from operations
$163,745K
Changes in fair values of
equity method...
$141,433K
Interest and dividend
income
$21,086K
Changes in fair values of
equity and long-term...
$20,160K
Total operating
expenses
$143,922K
Income before
provision for income taxes
$326,862K
Interest expense
$16,698K
Other expense, net
-$2,864K
Selling, general and
administrative
$113,318K
Research and development
$30,604K
Net income and
comprehensive income
$271,165K
Income tax expense, net
$55,697K
Back
Back
Income Statement
source: myfinsight.com
Innoviva, Inc. (INVA)
Innoviva, Inc. (INVA)